Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TSH BiopharmROCO:8432 +1.00%91 Debt-to-Equity is 0.01 as of Jun. 2026, which is at its 10-year median of 0.01. GuruFocus rates ROCO:8432 with a GF Score™ of 91/100 and a GF Value™ of NT$68.62 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 814 Drug Manufacturers companies, TSH Biopharm ranks better than 99.88% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for TSH Biopharm's Debt-to-Equity or its related term are showing as below:
ROCO:8432'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.01 Max: 0.06
Current: 0.01
During the past 13 years, the highest Debt-to-Equity Ratio of TSH Biopharm was 0.06. The lowest was 0.00. And the median was 0.01.
ROCO:8432's Debt-to-Equity is ranked better than 99.88% of 814
companies
in the Drug Manufacturers industry
Industry Median: 0.28
vs ROCO:8432: 0.01
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
TSH Biopharm Debt-to-Equity Related Terms
TSH Biopharm Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for TSH Biopharm's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, TSH Biopharm's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TSH Biopharm Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TSH Biopharm's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where TSH Biopharm's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSH Biopharm (ROCO:8432) has a Debt-to-Equity of 0.01 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on TSH Biopharm and its competitors. This is near median its historical median of 0.01. According to the industry distribution chart, TSH Biopharm ranks #1 out of 814 companies in the Drug Manufacturers industry, placing it in the top 0.099999999999994%.
Is TSH Biopharm's Debt-to-Equity too high?
TSH Biopharm's current Debt-to-Equity of 0.01 is near median its 10-year median of 0.01. The Drug Manufacturers industry median Debt-to-Equity is 0.28. TSH Biopharm's value of 0.01 is 96.4% below this industry median. Based on the distribution chart, TSH Biopharm ranks #1 out of 814 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, TSH Biopharm has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TSH Biopharm's Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, TSH Biopharm ranks #1 out of 814 companies for Debt-to-Equity. This places TSH Biopharm in the top 0% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.28. TSH Biopharm's value of 0.01 is 96.4% below this benchmark. While the company's 10-year median is 0.01 vs. the industry median of 0.28, TSH Biopharm has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TSH Biopharm's current Debt-to-Equity of 0.01 is 96.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on TSH Biopharm and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TSH Biopharm's current Debt-to-Equity is 0.01, which is near median its own 10-year median of 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TSH Biopharm stock overvalued right now?
Based on GuruFocus' analysis, TSH Biopharm (ROCO:8432) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$68.62, compared to a current price of NT$50.60 — trading 26.3% below its estimated fair value. The current Debt-to-Equity is 0.01, which is near median its 10-year median of 0.01 and 96.4% below the Drug Manufacturers industry median of 0.28. TSH Biopharm's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For TSH Biopharm (ROCO:8432), the current Debt-to-Equity is 0.01 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TSH Biopharm (ROCO:8432) Overvalued in 2026?
Based on GuruFocus' analysis, TSH Biopharm stock appears to be undervalued.
The current stock price of NT$50.60 is trading 26.3% below its estimated GF Value™ of NT$68.62.
GuruFocus considers TSH Biopharm to be Modestly Undervalued.
Key valuation signals for ROCO:8432:
Debt-to-Equity: 0.01 (near median its 10-year median of 0.01)
GF Value™: NT$68.62 vs. price of NT$50.60 (26.3% below fair value)
Industry Position: 96.4% below the Drug Manufacturers median (#1 of 814)
No single metric tells the full story. See the ROCO:8432 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TSH Biopharm Corp Ltd is engaged in sale of a variety of pharmaceuticals, chemical drugs and engaged in biotechnology services. The company specializes in the development, manufacture, and marketing of branded drugs for chronic diseases. Key therapeutic areas include cardiovascular, central nervous system, gastroenterology, and severe chronic diseases, alongside precision medicine/genetic testing services .The Company's revenue is earned domestically. It earns majority of its revenue from the sale of Lozenges.
91GF Score
Get the complete analysis for ROCO:8432
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:8432 has been successfully added to your 
